Trusted results from the scientific community
UV-C Light Intervention as a Barrier against Airborne Transmission of SARS-CoV-2
Study results found that air treated by Violett successfully prevented virus transmission and is a significant advancement in air disinfection. Violett’s groundbreaking technology presents an effective solution for safe, clean air in healthcare facilities, schools, public spaces, and even homes.
background
SARS-CoV-2 continues to impact human health globally, with airborne transmission being a significant mode for transmission. In addition to tools like vaccination and testing, counter-measures that reduce viral spread in indoor settings are critical. This study aims to assess the efficacy of UV-C light, utilizing the Violett sterilization device, as a countermeasure against airborne transmission of SARS-CoV-2 in the highly susceptible Golden Syrian hamster model.
MEthods
Two cohorts of naïve hamsters were subjected to airborne transmission from experimentally infected hamsters; one cohort was exposed to air treated with UV-C sterilization, while the other cohort was exposed to un-treated air.
results
Treatment of air with UV-C light prevented the airborne transmission of SARS-CoV-2 from experimentally exposed hamster to naïve hamsters. Notably, this protection was sustained over a muti-day exposure period during peak viral shedding from hamsters.
conclusions
These findings demonstrate the efficacy of the UV-C light to mitigate airborne SARS-CoV-2 transmission. As variants to continue to emerge, UV-C light holds promise as a tool to reduce infections in diverse indoor settings, ranging from healthcare facilities to households. This study reinforces the urgency of implementing innovative methods to reduce airborne disease transmission and safeguard public health against emerging biological threats.
Violett performed 1,000,000x better than a competitor company in head to head viral load reduction in independent third party testing
Violett uses a proprietary UV-C light vortex chamber combined with HEPA filtration. Competitor uses HEPA and PCO technology.
Both studies used the same bacterial strain and the same testing scheme.
Test results are 1:1 comparable with Violett M ARE Report results.
Here is a closer look at how Violett performed after 60 minutes compared to our competition
Violett
MS2 Trials: Net LOG Reduction
Large Chamber, Impinger Sampling, Enumerated in Triplicate
Competitor
MS2 Trials: Net LOG Reduction
Large Chamber, Impinger Sampling, Enumerated in Triplicate
Efficacy of the Violett L Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
Purpose
This study was done to test a prototype version of the Violett L for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
background
This in-vitro study characterized the efficacy of Violett L, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MEthods
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett L, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, in order to quantify the reduction rate capability of the air purification device. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentration for each sampling point. Chamber control trial data, or natural decay rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
results
The device achieved an average log reduction of 6.45 +/- 0.28 within 30 minutes. This equates to a netlog reduction of 6.21 +/- 0.28 (> 99.9999%) when accounting for control losses. These results show that the Violett L device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4 net log (99.99%) reduction within eighteen (18) minutes.
conclusions
In conclusion, the Violett L device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within a short period of time by achieving a 6.21 (99.9999%) net log reduction within thirty (30) minutes. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.
Efficacy of the Violett M Standalone Indoor Air Purifier Against Aerosolized MS2 Bacteriophage
Purpose
This study was done to test a prototype version of the Violett M for its efficacy at reducing a single microorganism, the bacteriophage MS2, from indoor room air.
background
This in-vitro study characterized the efficacy of Violett M, indoor air purifier, to reduce respirable bioaerosol levels for a single viral bioaerosol from the air in a 16m3 stainless steel bioaerosol test chamber. The species selected for this study was the virus MS2, a bacteriophage, which is a recognized surrogate for more dangerous pathogenic organisms. MS2 is a non-enveloped ssRNA virus that is a common surrogate for influenza viruses and is a tentative surrogate for SARS-CoV-2.
MEthods
MS2 bacteriophage was aerosolized into a sealed 16m3 environmental bioaerosol chamber, containing the Violett M, using a Collison 24-Jet Nebulizer. The MS2 bioaerosols had a mass median aerodynamic diameter (MMAD) averaging at 0.7µm (700nm). Bioaerosol samples were taken, with impingers, at multiple time points throughout each trial, to quantify the reduction rate capability of the air purification device over time. The impinger samples were serially diluted, plated, incubated, and enumerated in triplicate to yield viable bioaerosol concentrations for each of the sampling timepoints. Chamber control trial data, or the natural loss rate, was subtracted from the device trial data to yield the net log reduction for each of the bioaerosol challenges.
results
The device achieved an average log reduction of -6.77 +/- 0.09 in 60 minutes. This equates to a net log reduction of 6.42 +/- 0.09 (> 99.999961%) when accounting for control losses. These results show that the Violett M device is extremely effective at the rapid removal of viral bioaerosols from room air, achieving a 4-net log (99.99%) reduction within thirty-five (35) minutes.
conclusions
In conclusion, the Violett M device achieved >4 net log reduction of MS2 bacteriophage bioaerosols within about thirty-five minutes and a 6.42 net log (>99.9999%) reduction within sixty (60) minutes of operation. It is anticipated that such a reduction should reduce the likelihood of individuals being exposed to and contracting airborne infectious diseases in any enclosed environment, medical or otherwise.